Tolerability and safety of the new anti-obesity medications (Q38237336)

31 August 2017

Tolerability and safety of the new anti-obesity medications (English)

1 reference

31 August 2017

0 references

Vojtech Hainer

1

1 reference

PubMed ID

25096956

31 August 2017

Irena Aldhoon-Hainerová

series ordinal

2

1 reference

31 August 2017

1 September 2014

1 reference

31 August 2017

1 reference

31 August 2017

37

1 reference

31 August 2017

9

1 reference

31 August 2017

693-702

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-014-0206-3

31 August 2017

0 references

cites work

Management of Obesity in Adults: European Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Interdisciplinary European Guidelines on metabolic and bariatric surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Do we need anti-obesity drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

The FDA's assessment of two drugs for chronic weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Multicenter, placebo-controlled trial of lorcaserin for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Time series analyses of the effect of FDA communications on use of prescription weight loss medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Topiramate for migraine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Use of topiramate in pregnancy and risk of oral clefts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Topiramate-induced acute bilateral angle closure and myopia: pathophysiology and treatment controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

The cardiovascular safety of incretin-based therapies: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Randomized trial of lifestyle modification and pharmacotherapy for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Treatment modalities of obesity: what fits whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

Illicit online marketing of lorcaserin before DEA scheduling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0206-3

A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults

21 January 2018

1 reference

12 December 2020

Anti-obesity drugs: to be or not to be?

1 reference

12 December 2020

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

1 reference

12 December 2020

Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures

1 reference

12 December 2020

Beneficial health effects of modest weight loss

1 reference

12 December 2020

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2)

1 reference

12 December 2020

Obesity: preventing and managing the global epidemic. Report of a WHO consultation

1 reference

12 December 2020

Double-blind evaluation of the use of phentermine in treating obesity

1 reference

12 December 2020

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity

1 reference

12 December 2020

How should the obese patient be managed? Possible approaches to a national obesity management network

1 reference

12 December 2020

10.1007/S40264-014-0206-3

Identifiers

DOI

1 reference

PubMed ID

25096956

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

25096956